Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1;25(1):812.
doi: 10.1186/s12879-025-10496-3.

Clinical diagnostic accuracy of the HIV rapid test ACCU-TELL anti-HIV 1 + 2 in sub-Saharan African region

Veronique M Pirah  1 , Steeve Mbomo  1 , Armel Mintsa  1 , Amel Alame Emane  1 , Ngondziga Ongala Djeff Chirack  1 , Ndong Mebaley Telstar Ghestin  1 , Quenard Edwina Lorine  1 , Saidou Mahmoudou  2 , Joel Fleury Djoba Siawaya  1 , Paulin N Essone  3
Affiliations

Clinical diagnostic accuracy of the HIV rapid test ACCU-TELL anti-HIV 1 + 2 in sub-Saharan African region

Veronique M Pirah et al. BMC Infect Dis. .

Abstract

Human Immunodeficiency Virus (HIV) is still a major health challenge. Around 1.5 million people are newly infected with HIV in the world every year. Screening and identification of HIV infected individuals is a major health challenge in the management of this pandemic. The last decades have seen the development and deployment of HIV Rapid Diagnostic Tests (RDTs). These tests present numerous advantages in the management of HIV and are suitable in resource-limited settings. Unfortunately, many RDTs are deployed in low and middle income countries without primary evaluation in this setting. The current work evaluated the accuracy of Accu-Tell HIV rapid test in Sub-Saharan setting. We have performed a cross-sectional prospective study and included all patients visiting the national laboratory of public health in Libreville, Gabon, for a period of three months. We have selected RecombiLISA HIV1 + 2 Ab ELISA as gold standard. We have also included Determine HIV-1/2 Ag/Ab Combo as a control validated and recommended rapid test. Seven hundred forty-four participants visited our laboratory for HIV testing during the three-months study period with a mean age of 34 (SD: 14%) years old. ELISA and rapid tests (Determine and Accu-Tell) were performed on all study participants. 57, 61 and 62 participants were found positive for Accu-Tell, Determine and ELISA, respectively. For a sensitivity and specificity of 93% and 99%, respectively, Accu-Tell registered four (04) false positive and nine (09) false negative results. We observed six (06) false positive and seven (07) false negative results with Determine for a sensitivity and specificity of 90 and 99%, respectively. Accu-Tell and Determine have similar accuracy in detecting HIV infection in our setting. We have unfortunately observed a strong cross reaction between HIV1 and HIV2 with Accu-Tell. This test may not be used to differentiate HIV1 and HIV2.

Keywords: Accuracy; Diagnostic; HIV; Rapid test; Screening.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The current study was submitted and approved by both “Institutional Scientific Board” and the “Institutional Ethic Committee” of the National Laboratory of Public Health, Gabon. This study adhered to the Declaration of Helsinki and was explained to all study participants. An informed consent was obtained from all study participants before enrolment. Consent for publication: No personal information was included here. The work received the approval for published by the institutional scientific committee. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. «UNAIDS: Global HIV & AIDS statistics — Fact sheet». Consulted: 16 November 2024. Available on: https://www.unaids.org/en/resources/fact-sheet.
    1. Philippa E, Cheryl J, Carmen F, Rachel B. HIV and Hepatitis Testing: Global Progress, Challenges, and Future Directions. AIDS Rev. 2016;18(1):3–14. - PubMed
    1. Xiaoxing Q, Lori S, Paul Y, Debra JE, Renu D, Phaedre M, Xiao YW, Megan S, Priscilla S, George JD, et al. Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2017;92:62–8. - PubMed
    1. Luca V, Claudia M, Giuseppe P. Fourth generation assays for HIV testing. Expert Rev Mol Diagn. 2016;16(7):723–32. - PubMed
    1. Laura GW, Muazzam N, Robert WC, Eric R, Steven FE, Angela BH, Joan D, Jennifer R, Frederick SN, James EM, et al. Acute Infections, Cost per Infection and Turnaround Time in Three United States Hospital Laboratories Using Fourth-Generation Antigen-Antibody Human Immunodeficiency Virus Immunoassays. Open Forum Infect Dis. 2015;3(1):ofv188. - PMC - PubMed

MeSH terms

LinkOut - more resources